leadf
logo-loader
viewInotek Pharmaceuticals

Inotek Pharmaceuticals to raise US$50mln through convertible issue

Money raised will fund both testing of trabodenoson as a monotherapy and as a fixed-dose combination

picture of person taking eyedrops
Glaucoma is one of Inotek's areas of focus

Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) is to raise US$50mln for its eye pressure treatment trabodenoson through an issue of convertible senior notes.

The notes will pay interest at 5.75% and convert at a price of US$8.02 per share.

Money raised will fund both testing of trabodenoson as a monotherapy and as a fixed-dose combination with another drug, latanoprost, for the reduction of intraocular pressure.

Cowen and Company and Piper Jaffray will run the book jointly with an option to buy an additional US$7.5mln of notes if demand is sufficient.

Interest will be payable twice a year and the notes be convertible at the option of holders until the 2021 maturity date.

Inotek specialises in therapies for glaucoma and other eye diseases.

--updates for coupon and conversion price --

 

Quick facts: Inotek Pharmaceuticals

Price: - -

NASDAQ:ITEK
Market: NASDAQ
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

FansUnite Entertainment pleased Canada taking a look at allowing single...

FansUnite Entertainment (CSE: FANS- OTCQB: FUNFF) President Darius Eghdami joined Steve Darling from Proactive with news the company is hailing the Canadian government’s decision to introduce legislation that would legalize single-event sports betting in Canada. Eghdami talks about why that...

31 minutes ago

2 min read